gene on cardiovascular mortality, Tanus-Santos et al. recalled that the former SNP alters the gene responsiveness to statins: statins would up-regulate eNOS expression (2) more potently in -786C homozygous (3) and therefore, these subjects would generate more NO while on statins than subjects with the other genotypes. Accordingly, atorvastatin increased NO availability and reduced inflammatory marker concentrations in CC, but not in TT healthy men (4). However, we found no significant interaction between statin treatment and the T-786C SNP affecting cardiovascular mortality (1). Moreover, only a minority of our patients were on statins (5); therefore, this mechanistic explanation is unlikely.
Noncardiac Findings in Computed Tomography Coronary Angiography
The report by Onuma et al. (1) on noncardiac findings in multidetector computed tomography (MDCT) and the accompanying editorial comment by Rumberger (2) raise interesting issues. Onuma et al. (1) found that approximately 23% of 503 patients undergoing CT coronary angiography demonstrated significant noncardiac pathology requiring follow-up. This included 2 lung and 2 breast malignancies. Similarly, Baum et al. (3) have recently reported a high prevalence of extracardiac disease, including malignancies, among over a thousand patients undergoing MDCT.
Rumberger (2) suggests medico-legal and moral imperatives to seek noncardiac pathology. The patient's entire chest and upper abdomen have been irradiated, after all, and the imaging data are there awaiting reconstruction. Although this approach seems very reasonable, I believe we need to keep an open mind, recognizing the absence of hard evidence that the pursuit of extracardiac pathology leads to overall improved patient outcomes. Much of the noncardiac pathology, such as liver and renal cysts, is relatively unimportant and probably unrelated to the symptom of chest pain. With regard to more serious pathology, several questions arise: When found, are the newly discovered malignancies curable or amenable to treatment that prolongs life or improves quality of life? What percentage of patients requires repetitive imaging scans and further irradiation, and at what risk? What is the morbidity and mortality attendant to the biopsies and surgery for lesions that ultimately turn out to be benign? I believe we are at a crossroads where additional input from epidemiologists, oncologists, radiologists, cardiologists, and others is required to delineate further how far to widen or restrict the MDCT "field of view." Because large randomized prospective studies are unlikely in this regard, perhaps mathematical models of outcomes and costs could be formulated. Reply Dr. Fleet raises important questions, and there is legitimate concern that computed tomography (CT) scan "incidentalomas" can result in unnecessary or inappropriate testing at the expense of the insurance system and/or risk to the patient (1,2).
*Stephen Fleet, MD
The main issue regarding cardiac CT is, of course, coincident imaging of the adjacent lungs. Although lung cancer is the number one cause of cancer-related deaths in all men and women in America, the finding of variable size "lung nodules" is much more common than true malignant disease. Dr. Fleet asks: "When found, are the newly discovered malignancies curable or amenable to treatment that prolongs life or improves quality of life?" We may never have a complete answer to this inquiry. However, the overall survival rates for lung cancer are dismal, and the most recent report from the ELCAP (Early Lung Cancer Action Program) study (3) may provide a partial response. Henschke and colleagues (3) did screening lung scans in adults over 40 years old with either a history of cigarette smoking, an occupational exposure risk, or significant exposure to second-hand smoke, and they found that stage I lung cancers discovered (and treated) resulted in a projected 80% 10-year survival. These subjects are, coincidentally, at greatest risk for atherosclerotic heart disease. Importantly, however, lung cancer was found in only 484 (1.5%) of 31,567 screened individuals.
Dr. Fleet asks, "What is the morbidity and mortality attendant to the biopsies and surgery for lesions that ultimately turn out to be benign?" This is a rhetorical question as we do not have this information; however, in most instances biopsies are unnecessary, and follow-up low-dose CT scanning may be the only suggested consequence. In medicine we tend to "pass the buck" when it comes to test results that are unanticipated, and the best way to reduce unnecessary follow-up testing or procedures is physician education. There are guidelines published by the ELCAP investigators (4), which prescribe follow-up on the basis of lung nodule dimensions. More recently the Fleischner Society (5) described the workup of small pulmonary nodules incorporating smoking history as part of the clinical algorithm.
I agree that we are at a crossroad to define the clinical impact of diagnostic CT angiography and "extravascular" pathology, regardless of whether it involves the heart/chest, neck, abdomen, or periphery. The issue clearly extends beyond traditional singlespecialty medicine. Recently, a published commentary (6) 
